Ignite Creation Date:
2024-05-06 @ 2:00 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04187547
Status:
WITHDRAWN
Last Update Posted:
2023-04-14
First Post:
2019-11-29
Brief Title:
A Phase III Multi Regional Clinical Trial MRCT of Tricaprilin in Mild to Moderately Severe Probable Alzheimers Disease With Optional Open Label Extension
Sponsor:
Cerecin
Organization:
Cerecin
Study Overview
Official Title:
A Phase III 26-Week Double-blind Randomised Placebo-controlled Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimers Disease and Who Are Noncarriers of the APOE4 Allele
Status:
WITHDRAWN
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study replaced with a new study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is Phase 3 study multi-centre double-blind placebo controlled parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimers Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None